<?xml version='1.0' encoding='utf-8'?>
<document id="30471138"><sentence text="Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?"><entity charOffset="31-43" id="DDI-PubMed.30471138.s1.e0" text="lumefantrine" /><entity charOffset="57-67" id="DDI-PubMed.30471138.s1.e1" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.30471138.s1.e0" e2="DDI-PubMed.30471138.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30471138.s1.e0" e2="DDI-PubMed.30471138.s1.e1" /></sentence><sentence text="In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients"><entity charOffset="71-83" id="DDI-PubMed.30471138.s2.e0" text="lumefantrine" /><entity charOffset="135-145" id="DDI-PubMed.30471138.s2.e1" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.30471138.s2.e0" e2="DDI-PubMed.30471138.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30471138.s2.e0" e2="DDI-PubMed.30471138.s2.e1" /></sentence><sentence text="" /><sentence text="This was a two-period, single sequence crossover study" /><sentence text=" In stage 1, 150 HIV-infected patients receiving nevirapine-based antiretroviral regimens were enrolled and genotyped for seven SNPs"><entity charOffset="49-59" id="DDI-PubMed.30471138.s5.e0" text="nevirapine" /></sentence><sentence text=" Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration"><entity charOffset="94-104" id="DDI-PubMed.30471138.s6.e0" text="nevirapine" /></sentence><sentence text=" Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs" /><sentence text=" Intensive sampling was conducted in selected patients from each group" /><sentence text=" In stage 2, patients received standard artemether-lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3"><entity charOffset="51-63" id="DDI-PubMed.30471138.s9.e0" text="lumefantrine" /><entity charOffset="79-89" id="DDI-PubMed.30471138.s9.e1" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.30471138.s9.e0" e2="DDI-PubMed.30471138.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30471138.s9.e0" e2="DDI-PubMed.30471138.s9.e1" /></sentence><sentence text="" /><sentence text="No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0"><entity charOffset="55-65" id="DDI-PubMed.30471138.s11.e0" text="nevirapine" /></sentence><sentence text="80-1" /><sentence text="25 no-effect boundaries" /><sentence text=" However, the number of patients with trough plasma nevirapine concentration below the 3400 ng ml-1 minimum effective concentration increased from 10% without artemether-lumefantrine (all extensive metabolizers) to 21% with artemether-lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers)"><entity charOffset="52-62" id="DDI-PubMed.30471138.s14.e0" text="nevirapine" /><entity charOffset="170-182" id="DDI-PubMed.30471138.s14.e1" text="lumefantrine" /><entity charOffset="235-247" id="DDI-PubMed.30471138.s14.e2" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.30471138.s14.e0" e2="DDI-PubMed.30471138.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30471138.s14.e0" e2="DDI-PubMed.30471138.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30471138.s14.e0" e2="DDI-PubMed.30471138.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30471138.s14.e1" e2="DDI-PubMed.30471138.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30471138.s14.e1" e2="DDI-PubMed.30471138.s14.e2" /></sentence><sentence text="" /><sentence text="This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co-administered with artemether-lumefantrine"><entity charOffset="159-169" id="DDI-PubMed.30471138.s16.e0" text="nevirapine" /><entity charOffset="205-217" id="DDI-PubMed.30471138.s16.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.30471138.s16.e0" e2="DDI-PubMed.30471138.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30471138.s16.e0" e2="DDI-PubMed.30471138.s16.e1" /></sentence><sentence text="" /></document>